EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms

Man Liu, Na Li, Hongzhen Tang, Luohai Chen, Xuemei Liu, Yu Wang, Yuan Lin, Yanji Luo, Shaozhen Wei, Wenli Wen, Minhu Chen, Jiaqian Wang und 2 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Man Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Pancreatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroendocrine neoplasms (NENs) represent clinically and genetically heterogeneous malignancies, thus a comprehensive understanding of underlying molecular characteristics, prognostic signatures, and potential therapeutic targets is urgently needed.

Methods

Next-generation sequencing (NGS) and immunohistochemistry were applied to acquire genomic and immune profiles of NENs from 47 patients.

Results

Difference was distinguished based on differentiation grade and primary localization. Poorly differentiated neuroendocrine carcinomas (NECs) and well-differentiated neuroendocrine tumors (NETs) harbored distinct molecular features; we observed that tumor mutational burden (TMB) and tumor neoantigen burden (TNB) were significantly higher in NECs versus NETs. Notably, we identified a 7-gene panel (MLH3, NACA, NOTCH1, NPAP1, RANBP17, TSC2, and ZFHX4) as a novel prognostic signature in NENs; patients who carried mutations in any of the 7 genes exhibited significantly poorer survival. Furthermore, loss of heterozygosity (LOH) and germline homogeneity in human leukocyte antigen (HLA) are common in NENs, accounting for 39% and 36%, respectively. Notably, HLA LOH was an important prognostic biomarker for a subgroup of NEN patients. Finally, we analyzed clinically actionable targets in NENs, revealing that TMB high (TMB-H) or gene mutations in TP53, KRAS, and HRAS were the most frequently observed therapeutic indicators, which granted eligibility to immune checkpoint blockade (ICB) and targeted therapy.

Conclusion

Our study revealed heterogeneity of NENs, and identified novel prognostic signatures and potential therapeutic targets, which directing improvements of clinical management for NEN patients in the foreseeable future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsCarcinoma, NeuroendocrinePancreatic NeoplasmsHumansPrognosisBiomarkers, TumorMutation

Stichwörter der Autor:innen

genomic profileheterogeneityimmune signatureneuroendocrine neoplasmsprognostic signaturetherapeutic target

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, People's Republic of China.
  • Department of Medicine, YuceBio Technology Co., Ltd, Shenzhen, People's Republic of China.
  • Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Liu, M., Li, N., Tang, H., Chen, L., Liu, X., Wang, Y., Lin, Y., Luo, Y., Wei, S., Wen, W., Chen, M., Wang, J., Zhang, N., & Chen, J. (2023). The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist. https://doi.org/10.1093/oncolo/oyad093

Vancouver

Liu M, Li N, Tang H, Chen L, Liu X, Wang Y, et al. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist. 2023. doi:10.1093/oncolo/oyad093

BibTeX
@article{Liu2023,
  author = {Liu, Man and Li, Na and Tang, Hongzhen and Chen, Luohai and Liu, Xuemei and Wang, Yu and Lin, Yuan and Luo, Yanji and Wei, Shaozhen and Wen, Wenli and Chen, Minhu and Wang, Jiaqian and Zhang, Ning and Chen, Jie},
  title = {The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad093}
}
Kostenlos starten →